Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions
Intraocular MelanomaMelanoma (Skin)
Interventions
BIOLOGICAL

ipilimumab

IV over 90 mins on day 1, wks 1,9,17,25,33,41,53 Dose: 3 mg/kg (Part I), 10 mg/kg (Part II)

BIOLOGICAL

Tyrosinase/gp100/MART-1 Peptides

(All subjects in Part I and HLA-A\*0201 positive subjects only in Part II): SC, day 1 of wks 1,3,5,7,9,11,17, 21,25,33,41,53 Dose: 1 mg peptide emulsified in 1 mL Montanide ISA 51 VG.)

Trial Locations (1)

33612-9497

H. Lee Moffitt Cancer Center and Research Institute at University of South Florida, Tampa

Sponsors
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Bristol-Myers Squibb

INDUSTRY

NCT00084656 - Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma | Biotech Hunter | Biotech Hunter